Evidence map›Paper›PMID 28405545›Full record

ArticleJournal of kidney cancer and VHL2017

Maslinic Acid Inhibits Proliferation of Renal Cell Carcinoma Cell Lines and Suppresses Angiogenesis of Endothelial Cells.

Parth Thakor, Wenzhe Song, Ramalingam B Subramanian, Vasudev R Thakkar, David A Vesey, Glenda C Gobe

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of kidney cancer and VHL, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Analysis of the Mechanism of Maslinic Acid on Papillary Thyroid Carcinoma Based on RNA-Seq Technology.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Parth ThakorCentre for Kidney Disease Research, School of Medicine, Translational Research Institute, The University of Queensland, Brisbane, Queensland, Australia; Department of General Surgery, Affiliated Hospital to Xuzhou Medical University, Xuzhou, China; B. R. D. School of Biosciences, Sardar Patel University, Vallabhvidyanagar, Gujarat, India; Department of Renal Medicine, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Wenzhe SongCentre for Kidney Disease Research, School of Medicine, Translational Research Institute, The University of Queensland, Brisbane, Queensland, Australia; Department of General Surgery, Affiliated Hospital to Xuzhou Medical University, Xuzhou, China; B. R. D. School of Biosciences, Sardar Patel University, Vallabhvidyanagar, Gujarat, India; Department of Renal Medicine, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Ramalingam B SubramanianCentre for Kidney Disease Research, School of Medicine, Translational Research Institute, The University of Queensland, Brisbane, Queensland, Australia; Department of General Surgery, Affiliated Hospital to Xuzhou Medical University, Xuzhou, China; B. R. D. School of Biosciences, Sardar Patel University, Vallabhvidyanagar, Gujarat, India; Department of Renal Medicine, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Vasudev R ThakkarCentre for Kidney Disease Research, School of Medicine, Translational Research Institute, The University of Queensland, Brisbane, Queensland, Australia; Department of General Surgery, Affiliated Hospital to Xuzhou Medical University, Xuzhou, China; B. R. D. School of Biosciences, Sardar Patel University, Vallabhvidyanagar, Gujarat, India; Department of Renal Medicine, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
David A VeseyCentre for Kidney Disease Research, School of Medicine, Translational Research Institute, The University of Queensland, Brisbane, Queensland, Australia; Department of General Surgery, Affiliated Hospital to Xuzhou Medical University, Xuzhou, China; B. R. D. School of Biosciences, Sardar Patel University, Vallabhvidyanagar, Gujarat, India; Department of Renal Medicine, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Glenda C GobeCentre for Kidney Disease Research, School of Medicine, Translational Research Institute, The University of Queensland, Brisbane, Queensland, Australia; Department of General Surgery, Affiliated Hospital to Xuzhou Medical University, Xuzhou, China; B. R. D. School of Biosciences, Sardar Patel University, Vallabhvidyanagar, Gujarat, India; Department of Renal Medicine, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Translational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the introduction of many novel therapeutics in clinical practice, metastatic renal cell carcinoma (RCC) remains a treatment-resistant cancer. As red and processed meat are considered risk factors for RCC, and a vegetable-rich diet is thought to reduce this risk, research into plant-based therapeutics may provide valuable complementary or alternative therapeutics for the management of RCC. Herein, we present the antiproliferative and antiangiogenic effects of maslinic acid, which occurs naturally in edible plants, particularly in olive fruits, and also in a variety of medicinal plants. Human RCC cell lines (ACHN, Caki-1, and SN12K1), endothelial cells (human umbilical vein endothelial cell line [HUVEC]), and primary cultures of kidney proximal tubular epithelial cells (PTEC) were treated with maslinic acid. Maslinic acid was relatively less toxic to PTEC when compared with RCC under similar experimental conditions. In RCC cell lines, maslinic acid induced a significant reduction in proliferation, proliferating cell nuclear antigen, and colony formation. In HUVEC, maslinic acid induced a significant reduction in capillary tube formation in vitro and vascular endothelial growth factor. This study provides a rationale for incorporating a maslinic acid-rich diet either to reduce the risk of developing kidney cancer or as an adjunct to existing antiangiogenic therapy to improve efficacy.

Indexed as

angiogenesismaslinic acidproliferating cell nuclear antigenrenal cell carcinomavascular endothelial growth factor

Identifiers

PMID28405545
PMCPMC5364332
OpenAlexW2599436264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.